GeneDx Earnings Calls Show Why Reimbursement Determines the Economics of Genomic Testing
GeneDx’s May earnings shock (down 50%) exposed the financial consequences of a rapid shift toward genome sequencing. Its August and November calls trace the response: manage test mix, expand coverage, and improve collections. The latest results show progress, alongside a practical tradeoff between frictionless ordering and the documentation needed to secure payment.
ChatGPT 6 (Los Angeles, November 10, 2026). GeneDx’s November earnings discussion offers a detailed account of a problem that extends across advanced diagnostics: clinical demand can grow faster than the machinery that converts testing into payment. A laboratory can perform more tests, deliver valuable answers, and still collect less revenue per case than its business plan anticipated.
GenomeWeb captured the latest development in its November 10 headline, “GeneDx Shares Drop as Firm Starts Prioritizing Reimbursement Over Testing Volume.” The company is collecting more documentation before genome testing begins, accepting some delays and lower near-term volume expectations in exchange for a better prospect of reimbursement.
The stock reaction deserves perspective. Shares fell from approximately $65.72 to $54.83 on November 10, about 16.6%, while the five-day chart shows a decline from roughly $69 to $55. But the shares had also traded near $100 only a few months earlier, and their 52-week range was approximately $32 to $171. The latest decline sits within a much larger history of volatility.
The more informative story begins in May. That quarter exposed the economic problem; August described the repair strategy; November showed both progress and the friction involved in carrying it out.
May exposed the consequences of the genome transition
The striking early-May discontinuity in GeneDx’s stock chart followed its May 4 first-quarter report. On May 5, shares fell approximately 49%, closing at $34.51. The company reduced annual revenue guidance from $540–555 million to $475–490 million, a $65 million reduction at the midpoint. investors.com
The May earnings call explained that the shift toward genome had depressed blended average reimbursement. Management attributed $36 million of the annual revenue revision to reimbursement effects associated with product mix, $11 million to lower volume contributions from expansion markets, and $18 million to noncore businesses.
An important qualification accompanied that explanation. Management said contracted prices and collection rates within the respective products and channels had not materially changed in Q1. The immediate surprise was the composition of the business: a greater share of testing was moving into services with less favorable realized economics. The Motley Fool
This distinction matters. A laboratory does not need to experience an explicit payer price cut for its average revenue per test to fall. A change in what clinicians order—and the settings and payer populations in which they order it—can produce that result.
August laid out the repair strategy
By the August 3 second-quarter earnings call, GeneDx was describing a coordinated effort to improve reimbursement. Management emphasized test mix, coverage expansion, payer-specific workflows, and technology investment.
The underlying economics challenged an intuitive assumption that a broader assay should generate more revenue. GeneDx reported that genome’s contracted rates were lower than exome’s, while genome cost nearly twice as much to produce, largely because of reagents.
Collections added another constraint. Only about 32% of outpatient genome claims were being paid, versus 43% a year earlier. Management described the earlier acceptance of volume ahead of coverage as a market-development investment.
The company began moderating the transition. Genome’s share of outpatient insurance-based testing fell from nearly 40% in Q1 to 32% in Q2, with more emphasis on exome and reflex offerings. Genome remained the long-term destination, but the company was adapting the pace of adoption to the economics of delivering it. The Motley Fool
GeneDx reported Q2 revenue of $114.4 million, adjusted gross margin of 70%, and adjusted net income of $0.4 million. The improvement established a baseline for the next phase of the reimbursement work. ir.genedx.com
November made the operational tradeoff explicit
The November 9 third-quarter earnings call described what happens when a laboratory begins enforcing more of the payer’s documentation requirements before it performs the test.
GeneDx aligned genome workflows to obtain additional information from clinicians before laboratory testing started. This can improve the likelihood that the eventual claim satisfies the payer’s requirements. It can also extend the interval between receipt of an order and the start of testing.
Management reported cancellations, downgrades, and delayed starts. Accessions grew 28% year over year, while completed exome and genome result volume grew 25%. The company lowered its full-year expectations for exome and genome volume growth from at least 30% to at least 28%, and revenue growth for those services from at least 20% to at least 17%. GeneDx, LLC
Those changes illustrate why revenue cycle management is a clinical workflow issue as well as a billing function. The information needed for payment often originates in the ordering clinician’s office. If it is missing, the laboratory must obtain it, proceed with reimbursement uncertainty, or alter the testing pathway.
A process that is easy to order can generate strong demand while leaving substantial work unresolved downstream. Moving that work earlier makes the obstacle visible to clinicians and patients before testing proceeds.
What the denial analysis revealed
President Mark Gardner supplied one of the most consequential details of the November call. GeneDx’s analysis classified 62% of exome and genome denials as administrative or procedural. The remaining 38% involved disputes over clinical necessity or patients outside payer coverage policies.
The distinction identifies two different kinds of work. Administrative denials may respond to better documentation, authorization procedures, claim preparation, and follow-up. Coverage and medical-necessity problems may require new evidence, policy changes, or a different way of financing access.
The percentages describe the composition of denials. They do not mean that 62% of all tests were denied, or that correcting administrative processes will automatically recover 62% of lost revenue. Management’s assessment identifies the principal area of opportunity; the financial outcome still depends on execution.
For market access teams, the finding is particularly useful. Obtaining a favorable policy is only one part of commercialization. The laboratory must also demonstrate that a particular patient meets that policy’s requirements and present the claim in the form the payer will accept.
The financial results show progress with limits
The quarter’s results indicate improvement, although the year-over-year comparisons remain more difficult than the sequential ones.
| Measure | Q2 2026 | Q3 2026 |
|---|---|---|
| Total revenue | $114.4 million | $123.1 million |
| Exome and genome revenue | $100.3 million | $110.4 million |
| Exome and genome tests resulted | 30,785 | 32,134 |
| Blended average reimbursement per test | $3,258 | $3,436 |
| Genome share of outpatient insurance volume | 32% | 26% |
| Outpatient genome claims paid | 32% | 36% |
| Adjusted gross margin | 70% | 72% |
| Adjusted net income | $0.4 million | $8.6 million |
Sources: GeneDx quarterly disclosures and earnings calls; November 10 GenomeWeb reporting. www.fool.com
Blended reimbursement rose approximately 5% sequentially, helped by better genome collections and the shift toward exome. However, it remained below the approximately $3,800 reported in Q3 2025. Exome and genome volume increased 25% year over year, while revenue from those services increased 12%.
The product mix is important to interpreting the improvement. A higher blended reimbursement figure can reflect better collections, a larger share of better-reimbursed tests, or both. It should not automatically be read as an increase in payer prices.
Nor should the company’s losses be interpreted as evidence that every genome test loses money. GeneDx reported a Q3 GAAP net loss of $12.3 million while generating positive adjusted net income. Company profitability, product gross margins, and the economics of an individual claim are different measures.
Coverage must become operational before it becomes cash
The latest call also distinguished formal coverage from payment in practice. Management reported that 82% of outpatient genome volume was submitted to payers with positive coverage policies, up from 67% in Q2. Yet the genome collection rate was 36%; exome’s was approximately 32%.
These measures have different definitions and should not be subtracted to calculate a denial rate. Together, however, they show why a coverage announcement does not immediately resolve reimbursement.
Management attributed part of the genome collection improvement to plans following Carelon’s coverage policy. Medi-Cal implementation remained more difficult, with a larger benefit expected in 2027. Payers must translate coverage decisions into operating procedures, while laboratories must satisfy the patient-specific requirements. www.fool.com
GeneDx is investing in technology and artificial intelligence to make these processes easier to navigate. Such systems may help obtain and organize information, but they cannot by themselves create coverage for an excluded patient or establish clinical utility where a payer remains unconvinced.
The company’s appointment of Nicole Maassen as chief patient access officer, overseeing market access and government affairs, places these responsibilities prominently within its leadership structure.
PAMA adds a second reimbursement challenge
The collection problem is occurring alongside a prospective reduction in the reference prices used by many payer contracts.
The October 12 analysis of exome and genome pricing reported CMS’s preliminary PAMA median targets of $3,680.60 for exome, CPT 81415, and $3,018.72 for genome, CPT 81425. Genome’s ultimate target is approximately 18% below exome’s.
The reduction limits delay the crossover in actual Medicare payment:
| Rate or projection | Exome 81415 | Genome 81425 |
|---|---|---|
| 2026 CLFS rate | $4,780 | $5,031 |
| Preliminary capped 2027 payment | $4,063 | $4,276 |
| Projected 2028 payment | $3,680 | $3,635 |
| Preliminary ultimate median target | $3,680 | $3,018 |
The 2028 figures are projections assuming unchanged preliminary medians and reduction limits, rather than separately announced CMS rates. The reference-price inversion begins in 2028 under those assumptions. www.discoveriesinhealthpolicy.com
The business implication reaches beyond direct Medicare claims. On the November call, CFO Kevin Feeley said approximately 45% of company revenue was exposed to PAMA through CLFS-linked contracts. Management anticipated a mid-single-digit headwind to total revenue in 2027, while expecting collection improvements to offset or exceed it. www.fool.com
Those are separate forces. Improving the percentage of tests paid can raise revenue even while the payment benchmark declines. Conversely, growing test volume does not guarantee revenue growth if collections weaken or the reference rate falls.
The next stage is a test of execution
GeneDx’s three earnings discussions describe an evolving response to the same economic challenge. May revealed the consequences of a faster genome transition. August established the repair strategy. November demonstrated an initial improvement in reimbursement and margins, while exposing the delays and ordering friction that the strategy can create.
The company retained its full-year revenue range of $475–490 million and raised its adjusted net income outlook to approximately $12 million, even as it reduced exome and genome growth expectations. That combination explains the tension facing investors: improving economics per test can coexist with a more cautious near-term growth outlook. GeneDx, LLC
The next evidence will come from sustained collections, the time required to move orders into testing, and the extent to which reimbursement improvements persist as genome utilization rises again. For the wider diagnostics sector, GeneDx provides a concrete example of how clinical adoption, coverage policy, laboratory operations, and payment must advance together for scientific capability to become a durable business.
